Skip to content
March 29, 2024

Equity.Guru

Investment information for the new generation

Search
Analysts say this specialty pharma stock is on track for a record $100 million USD 2023

Analysts say this specialty pharma stock is on track for a record $100 million USD 2023

Medexus Pharmaceuticals (MDP.T), a Canadian specialty pharma company servicing both the Canadian and American markets, has built a sizeable drug portfolio with continuing growth potential.  It’s already been a good year for revenues and now analyst estimates suggest the innovative company’s combined sales could surpass $100 million USD in 2023.

Specialty drugs are used to treat complex chronic and life threatening conditions, making it a niche market with high margins and low marketing costs. The global specialty drug market was estimated at $1.81 billion USD in 2021 and is expected to reach $3.98 billion by 2027.

Ken d’Entremont, CEO and director, sits down with Chris Parry to talk about the company, its current growth potential and its treosulfan timeline.

Enjoy!

Related Posts

More on